Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Seragen, Inc.
Hopkinton/Westerly, Massachusetts/Rhode Island, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Seragen developed recombinant fusion proteins targeting specific cell surface receptors for cancer and immune-related diseases. Its lead product Ontak® (denileukin diftitox) was approved for cutaneous T-cell lymphoma after the company's acquisition by Ligand. Earlier clinical results showed statistical significance in psoriasis trials; other programs were discontinued or outlicensed.
- Therapeutic areas
- OncologyDermatologyCardiovascularEndocrinology
- Modalities
- Fusion proteinsRecombinant protein therapeutics
- Industry
- Biotech
02
Partnerships
Eli Lilly & Co.U.S. Surgical Corp.
Beyond the preview
Go deeper on Seragen, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seragen, Inc..